Nouveau Logo communiqué de presse.JPG
Theratechnologies complète le recrutement des six premières patientes de l’essai clinique de phase I mis à jour sur le sudocétaxel zendusortide dans le traitement du cancer de l’ovaire avancé
February 15, 2024 07:30 ET | Theratechnologies
Une étape importante de l’étude afin de poursuivre l’élan pour le principal CPM de la Société et son programme de développement clinique en oncologie MONTRÉAL, 15 févr. 2024 (GLOBE...
Nouveau Logo communiqué de presse.JPG
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
February 15, 2024 07:30 ET | Theratechnologies
Study milestone further extends momentum for Company’s lead PDC candidate and oncology clinical development program MONTREAL, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc....
Global Oncology Biomarkers Market
Oncology Biomarkers Market Forecast to Reach $23 Billion by 2027 According to New Research Report
January 24, 2024 13:27 ET | Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Oncology Biomarkers Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The recently published report on the...
22157.jpg
BRCA Tests Market Regulatory, Reimbursement and Forecasts to 2033
January 09, 2024 11:03 ET | Research and Markets
Dublin, Jan. 09, 2024 (GLOBE NEWSWIRE) -- The "BRCA Tests Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2033" report has been added to ResearchAndMarkets.com's offering....
Logo.png
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 11, 2023 08:30 ET | Imunon, Inc.
Accomplished pharmaceutical and biotechnology executive to lead IMUNON’s clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11, 2023 (GLOBE...
Emergen logo.png
Ovarian Cancer Drugs Market Size Worth USD 5.35 Billion in 2032 | Emergen Research
November 28, 2023 11:00 ET | Emergen Research
Vancouver, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The global ovarian cancer drugs market is set to experience substantial expansion, reaching a size of USD 2.40 Billion in 2022 and projecting an...
Emergen logo.png
Monoclonal Antibodies Market Size Worth USD 572.62 Billion in 2032 | Emergen Research
November 28, 2023 08:17 ET | Emergen Research
Vancouver, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The global monoclonal antibodies market size was USD 204.42 billion in 2022 and is expected to register a revenue CAGR of 10.8% during the forecast...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
November 27, 2023 07:00 ET | Genelux Corporation
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
Medicovestor Rectangle.PNG
Medicovestor, Inc announces the completion of an oversubscribed Seed Financing round to advance its novel Antibody Drug-Conjugate (ADC) platforms
November 20, 2023 10:00 ET | Medicovestor Inc
Medicovestor excels in oversubscribed Seed funding for its novel Anti-Drug Conjugate (ADC) platforms, gearing up for Series A in H1 2024.
AIMLogo.jpg
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
November 15, 2023 07:30 ET | AIM ImmunoTech Inc.
– Highlights continued execution across Ampligen® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will...